Drug intelligence / Profile preview

cladribine + cytarabine

Development stage: Unknown
Lead developer: St. Jude Children's Research Hospital
Modality: Small Molecules
Administration: Intravenous

Overview

Cladribine + cytarabine is a chemotherapeutic combination used primarily for the treatment of acute myeloid leukemia (AML). Cladribine is a purine analogue that exerts cytotoxic, proapoptotic, and antiproliferative effects on AML cells and inhibits DNA repair. Cytarabine is a pyrimidine nucleoside analogue that inhibits DNA synthesis. The combination works synergistically, as cladribine increases cytarabine triphosphate levels in leukemic cells, enhancing cytarabine's effectiveness. This combination has been studied in various clinical settings including newly diagnosed AML, elderly patients unfit for intensive chemotherapy, and relapsed/refractory AML.

Other names: CLAGCLAG-MCHALD-AC+cladribine

Targets

POLE (DNA polymerase epsilon)

Beyond the preview

Go deeper on cladribine + cytarabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cladribine + cytarabine.

Explore the full profile